Adjunct Targeted Temperature Management in Acute Severe Carbon Monoxide Poisoning
Study Details
Study Description
Brief Summary
This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
CO-poisoned patients are identified by medical history and carboxyhemoglobin (CO-Hb) value
5% (>10% in smokers). Patients presenting with acute CO poisoning will receive one HBO. ASCOP is defined as mental status showing response to painful stimulus or unresponsiveness requiring intubation for airway protection and ventilation support at the emerency department, and persistence of depressed mental status despite the HBO. After HBO treatment, eligible patients who provide consent will be randomly allocated to receive hypothermia, or normothermia treatment administered in a open label fashion except for blinding of outcome assessor.
Outcome measures will be administered at 1 month and 6 months after CO exposure. In addition, we will examine the differences in serum markers and mortality between the hypothermia and normothermia groups.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Hypothermia group Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours. |
Other: Targeted therapeutic hypothermia
Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
|
| Active Comparator: Normothermia group For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent. |
Other: Targeted therapeutic normothermia
Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
|
Outcome Measures
Primary Outcome Measures
- Main neurocognitive outcome [At 6 months after CO poisoning]
Global Deterioration Scale [range 1 - 7 (worst score)]
Secondary Outcome Measures
- Neurocognitive outcome [At 1 month after CO poisoning]
Global Deterioration Scale [range 1 - 7 (worst score)]
- Cerebral Performance Category [At 1 month and 6 months after CO poisoning]
Cerebral Performance Category [range 1 - 5 (worst score)]
- modified Rankin scale [At 1 month and 6 months after CO poisoning]
modified Rankin scale [range 0 - 6 (worst score)]
- Glasgow outcome scale [At 1 month and 6 months after CO poisoning]
Glasgow outcome scale [range 1 (worst score) - 5]
- mini-mental status exam [At 1 month and 6 months after CO poisoning]
mini-mental status exam
- Korean version of the Modified Barthel Index [At 1 month and 6 months after CO poisoning]
Korean version of the Modified Barthel Index
- Mortality in intensive care unit [Through study completion, an average of 6 months]
Number of participants with mortality in intensive care unit
- Mortality in intensive care unit [Through study completion, an average of 6 months]
Rate of participants with mortality in intensive care unit
- In-hospital mortality [Through study completion, an average of 6 months]
Number of participants with in-hospital mortality
- In-hospital mortality [Through study completion, an average of 6 months]
Rate of participants with in-hospital mortality
- Mortality [At 1, 3, and 6 months after CO poisoning]
Number of participants with all cause mortality
- Mortality [At 1, 3, and 6 months after CO poisoning]
Rate of participants with all cause mortality
- Length of stay in intensive care unit and hospital [Through study completion, an average of 6 months]
Length of stay in intensive care unit and hospital
- Pneumonia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Number of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.
- Pneumonia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Rate of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.
- Shock [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Number of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.
- Shock [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Rate of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.
- Bradycardia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Number of participants with dropped heart rate indicated drug or interventions
- Bradycardia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Rate of participants with dropped heart rate indicated drug or interventions
- Hypokalemia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Number of participants with serum K concentration <3.0 - 2.5 mmol/L
- Hypokalemia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Rate of participants with serum K concentration <3.0 - 2.5 mmol/L
- Hyperkalemia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Number of participants with serum K concentration >6.0 - 7.0 mmol/L
- Hyperkalemia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Rate of participants with serum K concentration >6.0 - 7.0 mmol/L
- Hyperglycemia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Number of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose
- Hyperglycemia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Rate of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose
- Hypophosphatemia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Number of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy
- Hypophosphatemia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Rate of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy
- Hypomagnesemia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Number of participants with serum magnesium <0.9 - 0.7 mg/dL
- Hypomagnesemia [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Rate of participants with serum magnesium <0.9 - 0.7 mg/dL
- Prolonged prothrombin Time International Normalized Ratio [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Number of participants with >2.5 x upper limit of the normal range and bleeding
- Prolonged prothrombin Time International Normalized Ratio [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Rate of participants with >2.5 x upper limit of the normal range and bleeding
- Prolonged activated partial thromboplastin time [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Number of participants with >2.5 x upper limit of the normal range and bleeding
- Prolonged activated partial thromboplastin time [During the intervention (therapeutic hypothermia or normothermia) period (72 hours)]
Rate of participants with >2.5 x upper limit of the normal range and bleeding
- S100ß (serum) [Within 14 days after CO exposure]
Concentration of S100ß (serum)
- Neuronal specific enolase (serum) [Within 14 days after CO exposure]
Concentration of neuronal specific enolase (serum)
- Brain magnetic resonance image (MRI) [Within 14 days after CO exposure]
Number of participants with brain injury in brain MRI
- Brain magnetic resonance image (MRI) [Within 14 days after CO exposure]
Rate of participants with brain injury in brain MRI
Eligibility Criteria
Criteria
Inclusion Criteria:
-
≥ 19 years.
-
Patients who received HBO within 24 hours for acute CO poisoning.
-
Patients who meet the definition of ASCOP (Patients incapable verbal obey after HBO).
-
Signed informed consent prior to study entry.
Exclusion Criteria:
-
Cardiac arrest before HBO
-
Previous neurocognitive disorders
-
Life-threatening underlying disease (ex: advanced cancer)
-
Evidence of co-ingestion of sedative or hypnotics confirmed by intravenous flumazenil administration or history taking at the emergency department
-
Absolute contraindication for TH (active severe bleeding and profound shock not controlled by vasoactive drugs)
-
No admission
-
The significant co-ingested drug levels, which are alter the consciousness, is confirmed from the drug analysis lab
-
Pregnancy
-
Burns
-
More than moderate burn or Inhalation burn
-
Burns complicated by other trauma
-
Electrical burn
-
Burns in high risk patients (Patients with chronic underlying diseases (i.e DM, ESRD, liver cirrhosis, etc) which may cause delays or aggravate the wound healing)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Wonju Severance Christian Hospital | Wonju | Gangwon | Korea, Republic of | 26426 |
| 2 | Inha University Hospital | Incheon | Korea, Republic of | 22332 |
Sponsors and Collaborators
- Wonju Severance Christian Hospital
- National Research Foundation of Korea
Investigators
- Principal Investigator: Yong Sung Cha, MD, Wonju Severance Christian Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
- TTM-COHB trial
- CR220011
- 2021-04-043